Last updated: May 26, 2026
Sensorcaine is the brand for bupivacaine hydrochloride marketed for local and regional anesthesia. In the US, supply is typically sourced through authorized manufacturers of the drug substance and finished sterile products, with distribution handled by wholesalers and specialty distributors. Patent and exclusivity timing is not a primary driver of “who supplies,” because bupivacaine HCl is widely genericized in many dosage presentations; instead, the key determinants of supply are sterile manufacturing capacity, CGMP compliance, NDA/ANDA control of labeling, and distribution availability.
Who manufactures Sensorcaine (bupivacaine HCl) and supplies the US market?
Featured snippet answer: Sensorcaine supply is controlled by the NDA holder and licensed distributors for the specific sterile presentation. In practice, US market coverage is split between branded supply (historically the original NDA product) and multiple ANDA suppliers for equivalent bupivacaine HCl injections.
Which “Sensorcaine” presentations are typically stocked?
Sensorcaine is sold as bupivacaine hydrochloride injection. In procurement, “Sensorcaine” orders often map to one of these sterile formats:
- Sensorcaine (bupivacaine HCl) injection, preservative-free or preserved
- Concentrations vary by product listing (common procurement SKUs align with standard bupivacaine strengths in sterile local anesthetic products)
Supply channels that control availability
For US purchasing, “supplier” usually means:
- Finished-dose manufacturer: the site(s) producing the injectable sterile product under NDA/ANDA.
- Labeler / applicant: the firm responsible for the ANDA/NDA labeling and regulatory filings.
- Wholesalers and specialty distributors: McKesson, Cardinal, AmerisourceBergen, and regional wholesalers typically carry bupivacaine anesthetic products.
- GPO and hospital pharmacy contracts: can shift orders toward the lowest-cost ANDA presentation even when “Sensorcaine” is requested in the EHR.
Procurement reality: hospital order sets and formularies may stock “bupivacaine HCl injection (generic)” under the same therapeutic substitution rules, so the practical “supplier” is often the ANDA holder behind the purchased NDC, not the brand name.
What is the Orange Book status of Sensorcaine (bupivacaine HCl) for injection?
Featured snippet answer: For older local anesthetic products like bupivacaine HCl injection, Orange Book status is commonly out of exclusivity or has limited remaining periods depending on the specific NDA and presentation. The controlling question for “supplier eligibility” is whether any unexpired patents or exclusivity blocks exist for the exact NDC strength and formulation.
How Orange Book listings translate into supplier count
If the Orange Book has no unexpired listed patents for a given NDC:
- multiple ANDA manufacturers can supply
- shortages typically trace to sterile capacity rather than IP
If the Orange Book still lists active patents (less common for legacy bupivacaine presentations in US):
- ANDA applicants may face Paragraph IV disputes
- the branded labeler may retain leverage through settlements
Which generic suppliers compete with Sensorcaine for bupivacaine HCl injection?
Featured snippet answer: The competitive set is usually multiple ANDA manufacturers of bupivacaine HCl injection across strengths and vial sizes.
What you should map in supplier vetting
When evaluating “suppliers,” procurement teams usually need to match:
- Exact NDC for the vial concentration and container size
- Preservative status (preserved vs preservative-free)
- Labeling differences (indications and administration instructions)
- Sterility assurance approach and batch release practices (sterile injectable sourcing)
Why “Sensorcaine request” often becomes “NDC substitution”
Many formularies treat brand requests as:
- therapeutic equivalent substitutions under pharmacy policy, or
- GPO contract-driven substitutions
So the actual supplier is determined at the NDC and contract level.
Which companies supply bupivacaine HCl injection in the US supply chain?
Featured snippet answer: The US bupivacaine HCl injection market is supplied by:
- the original brand labeler for Sensorcaine (for the specific NDC), and
- multiple ANDA manufacturers producing equivalent sterile bupivacaine HCl injections, distributed through major wholesalers and hospital purchasing channels.
Supplier verification checklist for bupivacaine HCl
For high-reliability procurement:
- confirm the NDC and strength
- verify ANDA/NDA holder and manufacturing sites
- check sterile fill-finish CGMP status
- align with hospital formulary and substitution policy
- screen for drug shortage alerts and alternate NDC lead times
When does Sensorcaine lose exclusivity or face Paragraph IV generic entry risk?
Featured snippet answer: For legacy bupivacaine HCl injection, exclusivity and listed patents typically no longer prevent generic entry for many NDCs; supply risk is more often driven by manufacturing capacity and sterile injectable availability than by patent barriers.
What to check for each Sensorcaine NDC strength
Because “Sensorcaine” can correspond to multiple NDCs:
- expiration of listed patents tied to that NDC
- expiration of any data exclusivity linked to that NDA
- whether any method-of-use or formulation patents exist for that exact presentation
If none are active, generic entry is not litigation-dependent.
How does formulation or method-of-use affect supplier options for Sensorcaine?
Featured snippet answer: For bupivacaine HCl injection, the supplier pool is often determined by the exact presentation (preserved vs preservative-free, concentration, container type). If a specific formulation has protected attributes (less common for classic bupivacaine presentations), that can narrow suppliers.
Typical differentiators that change the competitive set
- preservative content
- vial size
- concentration
- label indication and administration guidance
What manufacturing and sterile fill-finish constraints affect Sensorcaine supply?
Featured snippet answer: Shortages for sterile injectables like bupivacaine HCl injection are driven by:
- limited sterile manufacturing capacity
- fill-finish line disruptions
- batch release delays
- supply volatility from one or two key contract manufacturers
Practical supplier diversification levers
- qualifying multiple NDC sources within the same strength
- maintaining alternate contract suppliers for critical OR supplies
- stocking safety inventory for preserved vs preservative-free variants when clinically interchangeable in your protocol
Key Takeaways
- “Suppliers for Sensorcaine” in practice maps to (a) NDC-specific NDA/ANDA manufacturers and (b) distribution via major wholesalers.
- The US bupivacaine HCl injection market is typically multi-source, so availability depends more on sterile manufacturing capacity and contract supply than on IP.
- For procurement and tendering, the controlling variable is the exact NDC (strength, preservative status, vial size), not the brand name “Sensorcaine.”
- Supplier risk management should focus on NDC-level redundancy, batch release history, and drug shortage signals.
FAQs
-
How do I identify the correct Sensorcaine supplier by NDC?
Use the exact NDC for the vial concentration and container type, then map that NDC to the NDA/ANDA holder and labeled manufacturer on the FDA product listing.
-
Are hospitals allowed to substitute generic bupivacaine HCl for Sensorcaine?
In most settings, substitution is governed by formulary policy, state pharmacy rules, and clinical protocol; therapeutic equivalence is typically assessed at the NDC/product presentation level.
-
What causes bupivacaine HCl injection shortages even when generics exist?
Sterile fill-finish capacity, batch release constraints, and limited line availability can restrict supply for specific NDCs even in a multi-source market.
-
What presentation differences most affect clinician switching between Sensorcaine products?
Preservative status, concentration, vial size, and labeled administration details determine clinical interchangeability and procurement equivalence.
-
Does patent status affect which companies can supply Sensorcaine?
For many legacy bupivacaine HCl injections, patent barriers are usually not the limiting factor; the main constraints tend to be regulatory listing status for the exact NDC and sterile manufacturing capacity.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- FDA. National Drug Code Directory and Drug Products (by NDC).
- FDA. Drugs@FDA database.
